[HTML][HTML] Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized …
E Mansour, FF Bueno, JC de Lima-Júnior, A Palma… - Trials, 2021 - Springer
Abstract Background SARS-CoV-2, the virus that causes COVID-19, enters the cells through
a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a …
a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a …
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial
E Mansour, FF Bueno, JC de Lima-Júnior, A Palma… - Trials, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
SARS-CoV-2, the virus that causes COVID-19, enters the cells through a mechanism …
SARS-CoV-2, the virus that causes COVID-19, enters the cells through a mechanism …
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial.
E Mansour, FF Bueno, JC de Lima-Júnior, A Palma… - Trials, 2021 - go.gale.com
Background SARS-CoV-2, the virus that causes COVID-19, enters the cells through a
mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein …
mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein …
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial
E Mansour, FF Bueno, JC de Lima-Júnior, A Palma… - Trials, 2021 - search.proquest.com
Background SARS-CoV-2, the virus that causes COVID-19, enters the cells through a
mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein …
mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein …
[HTML][HTML] Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized …
E Mansour, FF Bueno, JC de Lima-Júnior… - …, 2021 - trialsjournal.biomedcentral.com
SARS-CoV-2, the virus that causes COVID-19, enters the cells through a mechanism
dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein highly …
dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein highly …
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial
E Mansour, FF Bueno, JC de Lima-Júnior… - Trials, 2021 - pubmed.ncbi.nlm.nih.gov
Background SARS-CoV-2, the virus that causes COVID-19, enters the cells through a
mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein …
mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein …
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial.
E Mansour, FF Bueno, JC de Lima-Júnior, A Palma… - Trials, 2021 - europepmc.org
Background SARS-CoV-2, the virus that causes COVID-19, enters the cells through a
mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein …
mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein …
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial.
E Mansour, FF Bueno, JC de Lima-Júnior, A Palma… - Trials, 2021 - search.ebscohost.com
Abstract < bold> Background: </bold> SARS-CoV-2, the virus that causes COVID-
19, enters the cells through a mechanism dependent on its binding to angiotensin …
19, enters the cells through a mechanism dependent on its binding to angiotensin …
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial
E Mansour, FF Bueno, JC de Lima-Junior, A Palma… - Trials, 2021 - bv.fapesp.br
Background: SARS-CoV-2, the virus that causes COVID-19, enters the cells through a
mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein …
mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein …
[PDF][PDF] Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled …
E Mansour, FF Bueno, JC de Lima-Júnior, A Palma… - 2021 - scholar.archive.org
Abstract Background: SARS-CoV-2, the virus that causes COVID-19, enters the cells through
a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a …
a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a …